Psoriasis biologics ‘don’t raise skin cancer risk’
A registry study shows no difference in risk for patients on biologic compared with other therapies, although this might not hold for those older than 60, researchers say
Patients with chronic plaque psoriasis face a similar risk of SCC or BCC whether they are treated with biologics or conventional immunomodulator therapies, UK data suggest.
The researchers note, however, that their analysis flagged older people on biologics had an 81% greater risk of SCC than peers on non-biologic systemic therapies.
